Skip to content

Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)

Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030704
Enrollment
Unknown
Registered
2020-03-10
Start date
2020-02-10
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The First People's Hospital of Jiangxia District, Wuhan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Novel coronavirus pneumonia is diagnosed met the fifth edition of the national health and Health Committee; 2. Respiratory rate in calm state >=30 times / min; OR Finger pulse oxygen saturation under rest and non oxygen absorption state <=93%; OR PO2/FiO2)<=300mmHg; OR PO2<60mmHg.

Exclusion criteria

Exclusion criteria: 1. Aged < 7-year-old; 2. previous arrhythmia; 3. previous chronic respiratory failure caused by other diseases, such as heart failure, thoracic deformity, structural lung disease, etc.; 4. hemodynamic instability; 5. severe immune deficiency or recent use of immunosuppressive agents; 6. allergic patients; 7. estimated survival time less than 3 days; 8. dropout on the halfway as well as lose of follow-up.

Design outcomes

Primary

MeasureTime frame
PO2/FiO2;ROX INDEX;

Secondary

MeasureTime frame
WBC;PBML;Time of Support time;

Countries

China

Contacts

Public ContactHu Xingxing

Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine

huxingxing82@163.com+86 17327006987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026